Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse.12/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2018 Category: Urology & Nephrology Source Type: news

Treatment of Stage IV Kidney Cancer
Patients with Stage IV renal cell cancer have cancer that has spread to distant sites in the body, invaded directly into local structures, or has spread to more than one lymph node. Stage IV disease is also known as metastatic cancer.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Treatment of Stages I - III Kidney Cancer
Patients with Stage I renal cell cancer have a primary cancer that is less than 7 centimeters in size (about 3 inches). The cancer is limited to the kidney, and has not spread to lymph nodes or distant sites.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Treatment & Management of Kidney Cancer
Treatment for renal cell cancer is tailored to each individual and may include surgery, precision cancer medicines, immunotherapy and chemotherapy. Radiation therapy is not typically used for the treatment of renal cell cancer. The specific treatment depends on the stage and genomic profile of the cancer.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Keytruda- Inlyta Treatment Combination Improves Outcomes in Renal Cell Caner
The pivotal Phase 3 KEYNOTE-426 clinical trial investigating Keytruda (pembrolizumab) anti-PD-1 therapy in combination with Inlyta (axitinib), a tyrosine kinase inhibitor (TKI) improved both overall survival (OS) and delayed the time to cancer progression compared to Sutent (sunitinib) when used in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC).12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib Promising for Metastatic Renal Cell Carcinoma
Updated clinical trial results reveal Tivozanib superior to Nexavar and headed to the FDA for US approval.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Overview of Renal Cell Cancer
Symptoms, risk factors and diagnosis of Kidney (Renal Cell) Cancer.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
The most important prognostic factor when treating renal cell carcinoma (RCC) is tumor staging. Larger tumors (greater than 4 cm to 5 cm) need to be carefully assessed for the possibility of renal sinus invasion, according to a new review published Surgical Pathology Clinics.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news

Clinical Trials in Renal Cell Carcinoma
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.12/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 11, 2018 Category: Urology & Nephrology Source Type: news

An overview of renal cell carcinoma
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.12/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 10, 2018 Category: Urology & Nephrology Source Type: news

miR ‑122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
An analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney.11/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally.11/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 20, 2018 Category: Urology & Nephrology Source Type: news

Trials Presented at ESMO 2018
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
(eLife) Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Systemic Therapy Options for Renal Cell Carcinoma
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy
Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC).11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive assessment gene signatures for clear cell renal cell carcinoma prognosis
There are many prognostic gene signature models in clear cell renal cell carcinoma (ccRCC). However, different results from various methods and samples are hard to contribute to clinical practice. It is necessary to develop a robust gene signature for improving clinical practice in ccRCC. A method was proposed to integrate least absolute shrinkage and selection operator and multiple Cox regression to obtain mRNA and microRNA signature from the cancer genomic atlas database for predicting prognosis of ccRCC.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib Improves PFS in Highly Refractory RCC
The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib extends PFS in advanced renal cell carcinoma
Tivozanib extended PFS compared with sorafenib among patients with highly refractory advanced or metastatic renal cell carcinoma, according to randomized phase 3 study results released by the agent ’s manufacturer.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan
Sunitinib has been shown to offer clinical benefits during the treatment of advanced renal cell carcinoma. However, molecular targeting drugs are expensive and can have a significant impact on medical expenses.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas
Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company ’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Should RCC Patients With Nodal Disease be Reclassified?
A study shows stage III renal cell carcinoma patients with nodal disease may need to be reclassified. (Source: CancerNetwork)
Source: CancerNetwork - October 30, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news

Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news

Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.10/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

ASTRO: Stereotactic Ablative RT OK for RCC in Solitary Kidneys
FRIDAY, Oct. 26, 2018 -- For patients with renal cell carcinoma (RCC), stereotactic ablative radiotherapy (SABR) seems to be as safe and effective for patients with a solitary kidney as for those with bilateral kidneys, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2018 Category: Pharmaceuticals Source Type: news

High-dose, high-precision radiation therapy safe, effective for solitary kidney cancer patients with only one kidney
(American Society for Radiation Oncology) Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. Findings will be presented in a news briefing today at 12 p.m. from the American Society for Radiation Oncology (ASTRO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

' Revolutionary' Data to Be Presented at ESMO 2018'Revolutionary' Data to Be Presented at ESMO 2018
Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.10/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 8, 2018 Category: Urology & Nephrology Source Type: news

Differentiating Benign Renal Tumors From Chromophobe RCC
A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma
The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma
The dismal prognosis for patients with metastatic renal cell carcinoma (mRCC) has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Smoking, obesity, hypertension and chronic kidney disease are risk factors for kidney cancer.09/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 28, 2018 Category: Urology & Nephrology Source Type: news

Renal Cell Carcinoma Center of Excellence
We invite you to become a member of PracticeUpdate and the Renal Cell Carcinoma Center of Excellence, an expert-curated resource that ’s dedicated to practicing physicians. The Renal Cell Carcinoma Center of Excellence provides physicians with the most up to date information on patient care.09/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2018 Category: Urology & Nephrology Source Type: news